<DOC>
	<DOC>NCT01871415</DOC>
	<brief_summary>This multicenter, randomized, double-blind, placebo-controlled study will evaluate the efficacy, safety and tolerability of aleglitazar in combination with metformin in patients with Type 2 diabetes mellitus who are inadequately controlled with metformin monotherapy. Patients will be randomized to receive either aleglitazar 150 mcg orally daily or placebo for 26 weeks in combination with their pre-existing metformin regimen and dose.</brief_summary>
	<brief_title>A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Monotherapy</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Adult patient, &gt;/= 18 years of age Type 2 diabetes mellitus treated with stable metformin monotherapy for at least 12 weeks prior to screening; metformin dose should be &gt;/= 1500 mg/day (or individual maximum tolerated dose), but no more than the maximum dose specified in the label HbA1c &gt;/= 7% and &lt;/= 9.5% at screening or within 4 weeks prior to screening and at prerandomization visit Fasting plasma glucose &lt;/= 13.3 mmol/L (&lt;/= 240 mg/dL) at prerandomization visit Agreement to maintain diet and exercise habits implemented during the runin phase during the full course of the study Pregnant women, women intending to become pregnant during the study period, currently lactating women, or women of childbearing potential not using highly effective, medically approved birth control methods Diagnosis or history of: 1. Type 1 diabetes mellitus, diabetes resulting from pancreatic injury, or secondary forms of diabetes 2. Acute metabolic diabetic complications such as ketoacidosis or hyperosmolar coma within the past 6 months Any previous treatment with thiazolidinedione or with a dual PPAR agonist Any body weight lowering or lipoproteinmodifying therapy (e.g. fibrates) within 12 weeks prior to screening with the exception of stable (&gt;= 1 month) statin therapy Prior intolerance to fibrate Treatment with antidiabetic medication other than metformin in the last 12 weeks prior to screening Triglycerides (fasting) &gt; 4.5 mmol/L (&gt; 400 mg/dL) at screening or within 4 weeks prior to screening Clinically apparent liver disease Anemia at or within 4 weeks prior to screening Inadequate renal function Symptomatic congestive heart failure NYHA Class IIIV at screening Myocardial infarction, acute coronary syndrome or transient ischemic attack/stroke within 6 months prior to screening visit Known macular edema at screening or prior to screening visit Diagnosed and/or treated malignancy (except for basal cell skin cancer, in situ carcinoma of the cervix, or in situ prostate cancer) within the past 5 years Uncontrolled hypertension History of active substance abuse (including alcohol) within the past 2 years</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>